Celecoxib, rofecoxib, and acute temporary visual impairment

Publisher Website
Google Scholar
Abstract
Introduction We present evidence of acute severe temporary visual disturbance with two of the new selective anti-inflammatory cyclo-oxygenase-2 (COX 2) inhibitors. We report two cases, one of temporary blindness and one that suggests a visual field defect together with five other less specific reports of blurred or abnormal vision (table 1). These reports were received while monitoring celecoxib and rofecoxib in the New Zealand intensive medicines monitoring programme. This national programme monitors selected newly introduced drugs.1 Monitoring of the COX 2 inhibitors celecoxib and rofecoxib started in December 2000. View this table: In this window In a new window Table 1 Case reports of visual disturbance with COX 2 inhibitors Acknowledgments We thank the reporting doctors.

This publication has 4 references indexed in Scilit: